Abbvie and Biogen pull MS drug Zinbryta following urgent EMA safety review
pharmafile | March 5, 2018 | News story | Sales and Marketing | AQbbvie, Biogen, EMA, Europe, mulyiple sclerosis, pharma, zinbryta
Biogen and Abbvie have announced their intention to voluntarily withdraw their multiple sclerosis therapy Zinbryta (daclizumab) from all global markets following the decision by the European Medicines Agency to launch an urgent review after eight cases of serious inflammatory brain disorders were reported.
Seven of the cases were identified in Germany and one in Spain, and included encephalitis and meningoencephalitis. The pharma pair said in a release detailing the decision that they believed that “characterising the complex and evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated”.
“Biogen believes the voluntary worldwide withdrawal of Zinbryta, a treatment for relapsing multiple sclerosis, is in the best interest of patients,” commented Dr Alfred Sandrock, Executive Vice President and Chief Medical Officer at Biogen. “Biogen and AbbVie continue to prioritise patient safety and the care of multiple sclerosis patients worldwide.”
To this end, the pair said that they will continue to work with regulatory bodies and healthcare providers to ensure an effective withdrawal and support Zinbryta patients.
Zinbryta was approved in the US in 2016, where it is marketed by Abbvie; Biogen handles marketing duties in Europe, Canada and Switzerland. The drug generated $107 million last year for the two companies, and is used in around 3,000 patients across the world today.
Matt Fellows
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Biogen and Stoke report positive results for Dravet syndrome drug
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …
